FDA to consider cardiovascular risk with ADHD drugs.(Briefly Noted)(Attention deficit hyperactivity disorder)(Brief article)

The Food and Drug Administration (FDA) has called for a new government study of drugs to treat attention-deficit hyperactivity disorder (ADHD), responding to accumulating reports of serious adverse events in both children and adults, including sudden death, strokes, heart attacks and hypertension. The Associated Press reported (Jan. 4) that last year the FDA's Canadian counterpart, Health Canada, removed Adderall XR from the market for six months following reports of 20 sudden deaths and 12 strokes in adults and children. The …